Common Chemo Combinations with Yervoy
Yervoy (ipilimumab), a CTLA-4 inhibitor from Bristol Myers Squibb, pairs with chemotherapy in several approved regimens, mainly for melanoma and lung cancer. These boost immune response alongside chemo's tumor-killing effects.
Yervoy Plus Chemo for Melanoma
In advanced melanoma, Yervoy combines with nivolumab (Opdivo) and two chemo drugs:
- Dacarbazine: Used in the triplet regimen for unresectable or metastatic melanoma. This approval came from the CheckMate 067 trial, showing improved survival.[1]
- Carboplatin plus paclitaxel: Another option for first-line treatment in metastatic melanoma, particularly when BRAF mutations are absent.[2]
Yervoy in Lung Cancer Regimens
For metastatic non-small cell lung cancer (NSCLC):
- Yervoy joins nivolumab, pemetrexed, and carboplatin as first-line therapy for nonsquamous NSCLC without EGFR/ALK mutations. The CheckMate 9LA trial supported this, with progression-free survival benefits over chemo alone.[3]
This is the primary chemo-inclusive combo here.
Other Chemo Pairings in Trials
Ongoing studies test Yervoy with:
- Gemcitabine plus cisplatin for biliary tract cancers.
- FOLFOX (folinic acid, fluorouracil, oxaliplatin) in colorectal cancer trials.
These remain investigational, not FDA-approved for routine use.[4]
How These Combos Work and Risks
Chemo shrinks tumors quickly, while Yervoy enhances T-cell activity for longer control. Risks include heightened immune-related adverse events like colitis or pneumonitis, plus standard chemo toxicities (nausea, neuropathy). Dosing varies by regimen—e.g., Yervoy 1 mg/kg every 6 weeks in NSCLC.[1][3]
[1]: FDA Label for Yervoy
[2]: NCCN Melanoma Guidelines
[3]: CheckMate 9LA Trial (NEJM)
[4]: ClinicalTrials.gov Search for Ipilimumab + Chemotherapy